ritanserin has been researched along with Uremia in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The regular hemodialysis sessions every 2-3 days did not affect the elimination rate of ritanserin, as the terminal half-life in these patients (39 +/- 23 hr) is similar to that in healthy volunteers (41 +/- 14 hr)." | 2.67 | Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ( Heykants, J; Huang, ML; Koch, S; Kokot, F; Kuska, J; Van Peer, A; Zazgornik, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zazgornik, J | 1 |
| Kuska, J | 1 |
| Kokot, F | 1 |
| Koch, S | 1 |
| Van Peer, A | 1 |
| Huang, ML | 1 |
| Heykants, J | 1 |
1 trial available for ritanserin and Uremia
| Article | Year |
|---|---|
Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
Topics: Administration, Oral; Adult; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1991 |